Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.

Tejpar S, Yan P, Piessevaux H, Dietrich D, Brauchli P, Klingbiel D, Fiocca R, Delorenzi M, Bosman F, Roth AD.

Eur J Cancer. 2018 Jun 14;99:66-77. doi: 10.1016/j.ejca.2018.05.009. [Epub ahead of print]

PMID:
29909091
2.

Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF-mutant stage II and III colon cancer.

Dunne PD, Coleman HG, Bankhead P, Alderdice M, Gray RT, McQuaid S, Bingham V, Loughrey MB, James JA, McCorry AMB, Gilmore A, Holohan C, Klingbiel D, Tejpar S, Johnston PG, McArt DG, Di Nicolantonio F, Longley DB, Lawler M.

Oncotarget. 2018 Feb 13;9(17):13834-13847. doi: 10.18632/oncotarget.24481. eCollection 2018 Mar 2.

3.

Vitamin D levels in Swiss breast cancer survivors.

Baumann M, Dani SU, Dietrich D, Hochstrasser A, Klingbiel D, Mark MT, Riesen WF, Ruhstaller T, Templeton AJ, Thürlimann B.

Swiss Med Wkly. 2018 Jan 29;148:w14576. doi: 10.4414/smw.2018.14576. eCollection 2018 Jan 29.

4.

Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).

von Moos R, Koeberle D, Schacher S, Hayoz S, Winterhalder RC, Roth A, Bodoky G, Samaras P, Berger MD, Rauch D, Saletti P, Plasswilm L, Zwahlen D, Meier UR, Yan P, Izzo P, Klingbiel D, Bärtschi D, Zaugg K; Swiss Group for Clinical Cancer Research (SAKK).

Eur J Cancer. 2018 Jan;89:82-89. doi: 10.1016/j.ejca.2017.11.005. Epub 2017 Dec 11.

PMID:
29241084
5.

Absence of evidence is not evidence of absence: the case of non-inferiority.

Klingbiel D, Thürlimann B, Brauchli P, von Moos R.

Ann Oncol. 2017 Dec 1;28(12):3100-3101. doi: 10.1093/annonc/mdx498. No abstract available.

PMID:
28945840
6.

24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling.

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M.

J Transl Med. 2017 Mar 30;15(1):66. doi: 10.1186/s12967-017-1174-z.

7.

Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort.

Juskevicius D, Jucker D, Klingbiel D, Mamot C, Dirnhofer S, Tzankov A.

J Hematol Oncol. 2017 Mar 17;10(1):70. doi: 10.1186/s13045-017-0438-7.

8.

Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: A systematic review and meta-analysis.

Datta NR, Stutz E, Liu M, Rogers S, Klingbiel D, Siebenhüner A, Singh S, Bodis S.

Gynecol Oncol. 2017 May;145(2):374-385. doi: 10.1016/j.ygyno.2017.01.033. Epub 2017 Feb 7. Review.

PMID:
28188016
9.

Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M.

J Thorac Oncol. 2017 Apr;12(4):681-688. doi: 10.1016/j.jtho.2016.12.003. Epub 2016 Dec 19.

10.

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.

Pagani O, Klingbiel D, Ruhstaller T, Nolè F, Eppenberger S, Oehlschlegel C, Bernhard J, Brauchli P, Hess D, Mamot C, Munzone E, Pestalozzi B, Rabaglio M, Aebi S, Ribi K, Rochlitz C, Rothgiesser K, Thürlimann B, von Moos R, Zaman K, Goldhirsch A; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2017 Feb 1;28(2):305-312. doi: 10.1093/annonc/mdw622.

11.

Outcome of Men With Relapse After Adjuvant Carboplatin for Clinical Stage I Seminoma.

Fischer S, Tandstad T, Wheater M, Porfiri E, Fléchon A, Aparicio J, Klingbiel D, Skrbinc B, Basso U, Shamash J, Lorch A, Dieckmann KP, Cohn-Cedermark G, Ståhl O, Chau C, Arriola E, Marti K, Hutton P, Laguerre B, Maroto P, Beyer J, Gillessen S.

J Clin Oncol. 2017 Jan 10;35(2):194-200. Epub 2016 Nov 28.

12.

A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.

Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O; Swiss Group for Clinical Cancer Research.

J Thorac Oncol. 2016 Nov;11(11):1846-1855. doi: 10.1016/j.jtho.2016.05.032. Epub 2016 Jun 14.

13.

Hyperthermia and radiotherapy with or without chemotherapy in locally advanced cervical cancer: a systematic review with conventional and network meta-analyses.

Datta NR, Rogers S, Klingbiel D, Gómez S, Puric E, Bodis S.

Int J Hyperthermia. 2016 Nov;32(7):809-21. doi: 10.1080/02656736.2016.1195924. Epub 2016 Aug 14. Review.

PMID:
27411568
14.

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

PMID:
27277747
15.

Hyperthermia and Radiation Therapy in Locoregional Recurrent Breast Cancers: A Systematic Review and Meta-analysis.

Datta NR, Puric E, Klingbiel D, Gomez S, Bodis S.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1073-87. doi: 10.1016/j.ijrobp.2015.12.361. Epub 2015 Dec 21. Review.

PMID:
26899950
16.

Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer.

Yan P, Klingbiel D, Saridaki Z, Ceppa P, Curto M, McKee TA, Roth A, Tejpar S, Delorenzi M, Bosman FT, Fiocca R.

Clin Cancer Res. 2016 Jun 15;22(12):3037-47. doi: 10.1158/1078-0432.CCR-15-0939. Epub 2016 Feb 9.

17.

Days spent in acute care hospitals at the end of life of cancer patients in four Swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Konzelmann I, Mousavi M, Clough-Gorr KM, Szucs T, Schwenkglenks M, Pestalozzi BC.

Eur J Cancer Care (Engl). 2017 Jul;26(4). doi: 10.1111/ecc.12453. Epub 2016 Feb 9.

PMID:
26856977
18.

Microsatellite Instability and BRAF and KRAS Mutations in Stage III Colon Cancer: Requirements for Accurate Prognosis Assessment.

Klingbiel D, Tejpar S.

JAMA Oncol. 2016 Jan 14. doi: 10.1001/jamaoncol.2015.5226. [Epub ahead of print] No abstract available.

PMID:
26768497
19.

The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06).

Strasser F, Blum D, von Moos R, Cathomas R, Ribi K, Aebi S, Betticher D, Hayoz S, Klingbiel D, Brauchli P, Haefner M, Mauri S, Kaasa S, Koeberle D; Swiss Group for Clinical Cancer Research (SAKK).

Ann Oncol. 2016 Feb;27(2):324-32. doi: 10.1093/annonc/mdv576. Epub 2015 Dec 8.

20.

Weekly carboplatin in combination with weekly paclitaxel in the treatment of metastatic non-small cell lung cancer: a single center 10-year experience.

Volk V, Cathomas R, Mark M, von Moos R, Klingbiel D, Brossart P, Mey U.

Support Care Cancer. 2016 May;24(5):2119-2128. doi: 10.1007/s00520-015-3015-z. Epub 2015 Nov 9.

PMID:
26553033
21.

High-throughput alternative splicing detection using dually constrained correspondence analysis (DCCA).

Baty F, Klingbiel D, Zappa F, Brutsche M.

J Biomed Inform. 2015 Dec;58:175-185. doi: 10.1016/j.jbi.2015.10.002. Epub 2015 Oct 19.

22.

Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07).

Mamot C, Klingbiel D, Hitz F, Renner C, Pabst T, Driessen C, Mey U, Pless M, Bargetzi M, Krasniqi F, Gigli F, Hany T, Samarin A, Biaggi C, Rusterholz C, Dirnhofer S, Zucca E, Martinelli G.

J Clin Oncol. 2015 Aug 10;33(23):2523-9. doi: 10.1200/JCO.2014.58.9846. Epub 2015 Jul 6. Erratum in: J Clin Oncol. 2015 Sep 20;33(27):3074.

PMID:
26150440
23.

Single Nucleotide Polymorphism (rs4932178) in the P1 Promoter of FURIN Is Not Prognostic to Colon Cancer.

Declercq J, Jacobs B, Biesmans B, Roth A, Klingbiel D, Tejpar S, Creemers JW.

Biomed Res Int. 2015;2015:321276. doi: 10.1155/2015/321276. Epub 2015 Jun 7.

24.

Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.

Tzankov A, Leu N, Muenst S, Juskevicius D, Klingbiel D, Mamot C, Dirnhofer S.

J Hematol Oncol. 2015 Jun 14;8:70. doi: 10.1186/s13045-015-0168-7.

25.

Treatment outcome and patterns of relapse following adjuvant carboplatin for stage I testicular seminomatous germ-cell tumour: results from a 17-year UK experience.

Chau C, Cathomas R, Wheater M, Klingbiel D, Fehr M, Bennett J, Markham H, Lee C, Crabb SJ, Geldart T.

Ann Oncol. 2015 Sep;26(9):1865-70. doi: 10.1093/annonc/mdv254. Epub 2015 Jun 2.

PMID:
26037797
26.

Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial).

Franzini A, Baty F, Macovei II, Dürr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche MH.

Clin Cancer Res. 2015 Dec 1;21(23):5253-63. doi: 10.1158/1078-0432.CCR-14-3135. Epub 2015 Apr 28.

27.

Improved survival of older patients with multiple myeloma in the era of novel agents.

Mey UJ, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F.

Hematol Oncol. 2016 Dec;34(4):217-223. doi: 10.1002/hon.2205. Epub 2015 Apr 21.

PMID:
25898820
28.

Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study.

Varga Z, Cassoly E, Li Q, Oehlschlegel C, Tapia C, Lehr HA, Klingbiel D, Thürlimann B, Ruhstaller T.

PLoS One. 2015 Apr 17;10(4):e0123435. doi: 10.1371/journal.pone.0123435. eCollection 2015.

29.

Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial.

Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2015 Jan;26(1):126-32. doi: 10.1093/annonc/mdu499. Epub 2014 Oct 30.

PMID:
25361982
30.

Cancer-related therapies at the end of life in hospitalized cancer patients from four Swiss cantons: SAKK 89/09.

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr K, Szucs T, Pestalozzi BC, Schwenkglenks M.

Oncology. 2015;88(1):18-27. doi: 10.1159/000367629. Epub 2014 Sep 26.

31.

Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features.

Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan P, Roth AD, Klingbiel D, Bosman FT, Delorenzi M, Tejpar S.

Ann Oncol. 2014 Oct;25(10):1995-2001. doi: 10.1093/annonc/mdu275. Epub 2014 Jul 23.

PMID:
25057166
32.

Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05).

Joerger M, Baty F, Früh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M.

Lung Cancer. 2014 Aug;85(2):306-13. doi: 10.1016/j.lungcan.2014.04.014. Epub 2014 May 29.

PMID:
24928469
33.

Measurement or estimation of glomerular filtration rate in seminoma patients: quite another cup of tea.

Fehr M, Geldart T, Klingbiel D, Cathomas R.

Eur J Cancer. 2014 Aug;50(12):2176-7. doi: 10.1016/j.ejca.2014.04.028. Epub 2014 Jun 7. No abstract available.

PMID:
24915777
34.

Delivery of health care at the end of life in cancer patients of four swiss cantons: a retrospective database study (SAKK 89/09).

Matter-Walstra KW, Achermann R, Rapold R, Klingbiel D, Bordoni A, Dehler S, Jundt G, Konzelmann I, Clough-Gorr KM, Szucs TD, Schwenkglenks M, Pestalozzi BC.

BMC Cancer. 2014 May 1;14:306. doi: 10.1186/1471-2407-14-306.

35.

Using the EuroQol EQ-5D in Swiss cancer patients, which value set should be applied?

Matter-Walstra K, Klingbiel D, Szucs T, Pestalozzi BC, Schwenkglenks M.

Pharmacoeconomics. 2014 Jun;32(6):591-9. doi: 10.1007/s40273-014-0151-0.

36.

Relevant risk of carboplatin underdosing in cancer patients with normal renal function using estimated GFR: lessons from a stage I seminoma cohort.

Cathomas R, Klingbiel D, Geldart TR, Mead GM, Ellis S, Wheater M, Simmonds P, Nagaraj N, von Moos R, Fehr M.

Ann Oncol. 2014 Aug;25(8):1591-7. doi: 10.1093/annonc/mdu129. Epub 2014 Mar 25.

PMID:
24669017
37.

What can we learn from the ZOOM trial?

Hayoz S, Klingbiel D, Brauchli P, Moos Rv.

Lancet Oncol. 2013 Sep;14(10):e388. doi: 10.1016/S1470-2045(13)70345-0. No abstract available.

PMID:
23993382
38.

Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer.

Hitz F, Ribi K, Li Q, Klingbiel D, Cerny T, Koeberle D.

Support Care Cancer. 2013 Nov;21(11):3085-93. doi: 10.1007/s00520-013-1886-4. Epub 2013 Jul 5.

PMID:
23828394
39.

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK).

Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6.

PMID:
23582881
40.

Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.

Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E.

J Natl Cancer Inst. 2012 Nov 7;104(21):1635-46. doi: 10.1093/jnci/djs427. Epub 2012 Oct 25. Erratum in: J Natl Cancer Inst. 2013 Jan 16;105(2):151-2.

PMID:
23104212
41.

Electronic monitoring of symptoms and syndromes associated with cancer: methods of a randomized controlled trial SAKK 95/06 E-MOSAIC.

Blum D, Koeberle D, Ribi K, Schmitz SF, Utiger U, Klingbiel D, Strasser F.

BMC Palliat Care. 2012 Sep 24;11:19. doi: 10.1186/1472-684X-11-19.

42.

Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).

Cathomas R, Rothermundt C, Klingbiel D, Bubendorf L, Jaggi R, Betticher DC, Brauchli P, Cotting D, Droege C, Winterhalder R, Siciliano D, Berthold DR, Pless M, Schiess R, von Moos R, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Clin Cancer Res. 2012 Nov 1;18(21):6049-57. doi: 10.1158/1078-0432.CCR-12-2219. Epub 2012 Sep 12.

43.

CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms.

Oppliger Leibundgut E, Rogenmoser-Dissler D, de Beer D, Porret NA, Zibellini S, Dürig J, Röth A, Klingbiel D, Baerlocher GM.

Leuk Res. 2012 Sep;36(9):1204-7. doi: 10.1016/j.leukres.2012.05.015. Epub 2012 Jun 25.

PMID:
22738889
44.

A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.

Renner C, Zinzani PL, Gressin R, Klingbiel D, Dietrich PY, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Trojan A, Bouabdallah K, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N; Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network.

Haematologica. 2012 Jul;97(7):1085-91. doi: 10.3324/haematol.2011.053173. Epub 2012 Feb 7.

45.

Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03).

Pesce GA, Klingbiel D, Ribi K, Zouhair A, von Moos R, Schlaeppi M, Caspar CB, Fischer N, Anchisi S, Peters S, Cathomas R, Bernhard J, Kotrubczik NM, D'Addario G, Pilop C, Weber DC, Bodis S, Pless M, Mayer M, Stupp R.

Eur J Cancer. 2012 Feb;48(3):377-84. doi: 10.1016/j.ejca.2011.10.016. Epub 2011 Nov 15.

PMID:
22093943
46.

Athrombogenic coating of long-term venous catheter for cancer patients: a prospective, randomised, double-blind trial.

Hitz F, Klingbiel D, Omlin A, Riniker S, Zerz A, Cerny T.

Ann Hematol. 2012 Apr;91(4):613-20. doi: 10.1007/s00277-011-1343-8. Epub 2011 Sep 29.

PMID:
21956636
47.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.

J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.

PMID:
20008640
48.

Expression profiling of human idiopathic dilated cardiomyopathy.

Grzeskowiak R, Witt H, Drungowski M, Thermann R, Hennig S, Perrot A, Osterziel KJ, Klingbiel D, Scheid S, Spang R, Lehrach H, Ruiz P.

Cardiovasc Res. 2003 Aug 1;59(2):400-11.

PMID:
12909323

Supplemental Content

Loading ...
Support Center